Over the past decade, Hydrix has been at the forefront of developing critical technology for clients who are building total artificial hearts and heart pump devices.
Cardiovascular disease (CVD) is the world’s leading cause of death. It afflicts 14% of the global population. As such, the devices market is expected to grow to US$70B by 2027. This represents a large & growing market opportunity for Hydrix.
We are therefore building on 20 years of experience in medtech product development to translate this knowhow into establishing Hydrix as a leading cardiovascular technology company.